FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
96 letters match. Newest first.
-
FoodPenn Herb Company, Ltd.
FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.
High risk -
DrugsPritam International Private Limited
Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.
High risk -
DrugsTSP Solutions Pte. Ltd.
FDA warns Singapore OTC drug maker TSP Solutions over missing release testing and component identity checks for sunscreens.
High risk -
DrugsZhejiang Gaorong Cosmetic Co., Ltd.
FDA cited Zhejiang Gaorong Cosmetic for OTC drug CGMP violations in component testing and quality unit oversight.
High risk -
DrugsTCI Co., Ltd BioCosme PABP BRANCH
FDA warns Taiwan OTC drug contract manufacturer TCI BioCosme over CGMP violations, including incomplete release and ingredient testing.
High risk -
DrugsBentley Laboratories LLC
Bentley Laboratories LLC was cited for CGMP violations and for marketing unapproved acne drugs.
High risk -
BiologicsNexCell Scientific Inc
NexCell Scientific markets an unapproved, unlicensed umbilical cord blood cell product with serious manufacturing violations.
High risk -
Drugskdc/one Chatsworth, Inc.
FDA warned kdc/one Chatsworth of CGMP violations in OTC drugs, including missing carcinogen testing and storage temperature failures.
High risk -
DrugsIsland Kinetics, Inc. d.b.a. CoValence Laboratories
Island Kinetics (CoValence Laboratories) made OTC acne drugs without process validation and shipped unapproved, misbranded acne products.
High risk -
DrugsSpa De Soleil, Inc.
FDA cites Spa De Soleil for CGMP violations in OTC topical drugs, including water system failures and missing component identity testing.
High risk -
DrugsSante Manufacturing Inc.
Sante Manufacturing’s OTC drugs have significant CGMP violations, including missing identity testing for a high-risk component and inadequate process validation and quality oversight.
High risk -
DrugsMacau-Union Pharmaceutical Limited
Macau-Union Pharmaceutical failed CGMP and sold unapproved, misbranded Bamboo Pharmacy OTC pain rubs in the U.S.
High risk -
FoodBest Buy Bones, Inc.
Best Buy Bones pet treats were found with Salmonella and serious animal-food safety and CGMP violations.
High risk -
FoodHearthy Foods, Inc.
FDA cited Hearthy Foods after an inspection for CGMP violations in RTE whey protein and dietary supplements, including allergen and pest issues.
High risk -
DrugsMicrobiological Testing & Consulting, LLC
FDA warned contract testing lab Microbiological Testing & Consulting over CGMP violations in drug product microbiological testing.
High risk -
DrugsPatcos Cosmetics Pvt. Ltd.
Patcos Cosmetics, an Indian OTC drug manufacturer, was cited for insanitary conditions and CGMP violations after a 2025 FDA inspection.
High risk -
DrugsSimtra BioPharma Solutions
FDA found contamination risks in Simtra's sterile drug manufacturing in Germany, including microbial recoveries, failed isolator tests, and inadequate decontamination.
High risk -
DrugsCosmetic Manufacturers Pty Ltd.
FDA warned Cosmetic Manufacturers Pty Ltd. that its Australian drug site was adulterated due to CGMP violations and placed its drugs on import alert.
High risk -
DrugsHTO Nevada, Inc. dba Kirkman
HTO Nevada dba Kirkman, an OTC drug contract manufacturer, was cited for CGMP violations including mislabeled reformulated drugs.
High risk -
DrugsWinder Laboratories, LLC
FDA warns Winder Laboratories of adulterated prescription drugs due to cleaning and facility failures.
High risk -
FoodLXR Biotech, LLC
FDA warns LXR Biotech over CGMP (manufacturing quality rules) failures for Eternal Energy supplements, making them adulterated (legally unfit as made).
Medium -
DrugsLiquidCapsule Manufacturing, LLC
LiquidCapsule Manufacturing failed CGMP (current good manufacturing practice) for OTC drugs, including component identity testing and process validation failures.
High risk -
DrugsGuangdong Renhe Guozhuang Biotechnology Co., Ltd.
FDA warns Guangdong Renhe Guozhuang Biotechnology over CGMP failures in OTC drug manufacturing.
High risk -
DrugsUriel Pharmacy, Inc.
Uriel Pharmacy's homeopathic ampule drugs are unapproved new drugs and were made under serious CGMP violations.
High risk -
FoodVidaslim Co.
Vidaslim Co. dietary supplements are adulterated by CGMP failures and misbranded by label violations.
Medium -
DrugsColumbia Cosmetics Manufacturing Inc.
Columbia Cosmetics Manufacturing Inc. made OTC sunscreen drugs without adequate current good manufacturing practice, including failed out-of-specification investigations and untested high-risk ingredients.
High risk -
DrugsEverlaan Organics, Inc. dba Maple Organics
FDA warns Maple Organics over OTC drug CGMP failures, unapproved new drugs, and misbranding.
High risk -
DrugsExela Pharma Sciences, LLC
Exela Pharma Sciences failed CGMP (current good manufacturing practice) for sterile injectable drugs, including invalidated sterility-media tests and inaccurate microbiology records.
High risk -
DrugsZhejiang Huahai Pharmaceutical Co., Ltd.
FDA warns Zhejiang Huahai Pharmaceutical over CGMP violations including dirty equipment, aseptic-area tape, and data integrity issues.
High risk -
DrugsAACE Pharmaceuticals, Inc.
AACE Pharmaceuticals distributed adulterated Lubricant PM Ointment made by CMO Brassica with CGMP violations and failed supplier qualification.
High risk -
DrugsHangzhou Glamcos Biotech Co., Ltd.
Hangzhou Glamcos Biotech’s OTC antibacterial wipes had CGMP violations and were unapproved and misbranded, FDA says.
High risk -
DrugsVegewax Candleworx Ltd.
FDA warns Vegewax Candleworx over CGMP violations in OTC drug manufacturing, including inadequate component testing and OOS investigations.
High risk -
BiologicsBioStem Life Sciences
FDA says BioStem Life Sciences made unapproved umbilical cord and amniotic products with significant CGMP violations.
High risk -
BiologicsXO Biologix, LLC
XO Biologix markets MaviX, an amniotic-fluid product, as an unapproved new drug and unlicensed biologic.
High risk -
DrugsSombra Cosmetics, Inc.
FDA warned Sombra Cosmetics of OTC drug CGMP violations, including inadequate water controls and component testing.
High risk -
DrugsBrands International Corporation
Brands International, a Canadian drug manufacturer, limited an FDA inspection and had manufacturing quality violations including mold contamination.
High risk -
DrugsGuangzhou Four E’s Scientific Co., Ltd.
FDA warns Guangzhou Four E’s over CGMP failures for OTC drugs, including a sterile-labeled product with inadequate sterility assurance.
High risk -
DrugsUnexo Lifesciences, Private Limited
FDA warned Unexo Lifesciences over serious CGMP violations, including data integrity failures and torn batch records for U.S.-bound drugs.
High risk -
DrugsZhejiang Qimei Cosmetics Co., Ltd.
Zhejiang Qimei Cosmetics drew an FDA warning for CGMP violations in sterile-labeled OTC isopropyl alcohol prep pads.
High risk -
DrugsOutin Futures Corp.
FDA warned Outin Futures, a Korean drug manufacturer, of CGMP violations and sunscreen misbranding after a March 2024 inspection.
High risk -
FoodRestorative Botanicals, LLC
FDA warns Restorative Botanicals over CGMP failures for two mushroom dietary supplements, including missing identity and toxic-element limits.
Medium -
DrugsAerosol and Liquid Packaging, Inc.
FDA warns Aerosol and Liquid Packaging on CGMP failures and unapproved antiseptic spray claims.
High risk -
DrugsRegenerative Processing Plant, LLC
FDA warns Regenerative Processing Plant over unapproved, misbranded Regener-Eyes eye drops and serious sterile manufacturing violations.
High risk -
DrugsCARsgen Therapeutics Corporation
FDA warns CARsgen over CGMP violations for investigational CAR T cell products at Durham facility.
High risk -
DrugsEugia Pharma Specialities Limited
FDA cited Eugia Pharma Specialities for CGMP violations at its India sterile injectable plant, including falsified records and contamination risks.
High risk -
DrugsNowrez & Ismail Shukri Company
FDA warns Jordanian OTC drug maker Nowrez & Ismail Shukri over CGMP violations and import alert.
High risk -
DrugsVelocity Pharma LLC
Velocity Pharma distributed eye drop drugs made by contract manufacturers with serious manufacturing and sanitation violations.
High risk -
DrugsGenuine Virgin Aloe Corp dba Triderma
FDA warned Triderma, an Anaheim OTC skin cream maker, of CGMP violations after a January 2024 inspection.
High risk -
DrugsAruba Aloe Balm N.V.
Aruba Aloe Balm N.V. made OTC drugs with methanol-contaminated ethanol and failed CGMP, prompting recall and import alert.
High risk -
DrugsCentral Admixture Pharmacy Services, Inc.
FDA warned Central Admixture Pharmacy Services' Allentown outsourcing facility over sterile drug contamination and CGMP failures.
High risk